Ⅲ期结直肠癌一线辅助化疗后卡培他滨维持治疗的临床评价

Clinical Evaluation on Capecitabine Maintenance Therapy in the Treatment of Stage Ⅲ Colorectal Cancer After First-Line Adjuvant Chemotherapy

目的评价Ⅲ期结直肠癌一线辅助化学治疗后卡培他滨维持治疗的疗效及安全性。方法收集医院Ⅲ期结直肠癌患者69例,完成根治性手术及一线化疗(XELOX方案)后,33例给予卡培他滨单药维持患者作为观察组,余36例随访观察患者作为对照组。结果 Kaplan-Meier曲线显示,观察组中位3年无进展生存期(PFS)高于对照组[(12.24±1.26)个月比(8.12±1.43)个月,P=0.043];观察组维持治疗期间不良反应发生率较联合化疗期间相比降低(P<0.05),观察组维持治疗期间与对照组同期不良反应发生率相比均无显著性差异(P>0.05)。结论结直肠癌一线化疗后予以单药卡培他滨维持治疗可显著延长患者3年PFS,可进而转化为总体生存率,且其耐受性好,值得临床推广。

Objective To evaluate the clinical effect and safety of capecitabine maintenance therapy in the treatment of stage Ⅲ colorectal cancer after first-line adjuvant chemotherapy.Methods Totally 69 patients with stage Ⅲ colorectal cancer were selected.After the completion of radical surgery and first-line chemotherapy（ XELOX regimen）, 33 patients were given capecitabine maintenance therapy（ the observation group）, and the another 36 patients were followed up（ the control group）.Results Kaplan-Meier curve showed that the median 3-year PFS of the observation group was longer than that of the control group [（12.24 ± 1.26） months vs.（8.12 ± 1.43）months, P = 0.043 ].During the maintenance chemotherapy period, the incidence rate of adverse reactions in the observation group was lower than that in the combined chemotherapy period（ P〈0.05）.During the maintenance therapy period,there was no significant difference in the inci dence rate of adverse reactions between the observation group and the control group（ P〈0.05）.Conclusion Capecitabine maintenance therapy in the treatment of colorectal cancer after first-line chemotherapy can significantly prolong the patients＇ 3-year PFS,which can then be converted to OS,and it is well tolerated and worthy of clinical promotion.